Cathal Friel

Influenza could be a major global issue due to low immunity caused by reduced infection

Study is being carried out under asthma human challenge study model

Healthy volunteers are administered a pathogenic or virulent strain of virus

Seen & heard: global tax rate above 15%; phasing out leasing of social housing; Poolbeg to seek Nasdaq listing

Infectious diseases specialist to list in London

Challenge study is providing valuable insight into biology of the virus, firm says

Company will use money from listing to meet costs for flu drug trials, develop assets

Company says reduction of capital will allow it to return value to its shareholders

Company says HVO-001 could be included as part of potential demerger

Seen and Heard: Quinlan bankruptcy case set for June; Hammerson stuck for Ilac tenants

Contract with US biotechnology company concerns a respiratory syncytial virus

Prophylactic spray could be used against Covid-19

Dublin-listed pharmaceutical services company says new deal will run for another year

Vaccine could be one of the first to provide long-term immunity from Covid-19

Open Orphan subsidiary to manage Phase 2 clinical trial for European pharma company

Guidelines will cover manufacture of agents for use in controlled infection studies

Contract guarantees annual revenue for Dublin listed company

Contract with UK government could be worth up to £10m

Company led by Cathal Friel recorded revenues of £7.1m for its first half

Paris subsidiary Venn Life Sciences to work with oncology study enrolling 750 subjects

Sectors include health and safety, pharma, crop protection and refrigeration

Dublin-listed pharmaceutical services company says contract is with top three pharma group